RxDoctor Payments DataLook up a doctor →

Louis Guzzi, MD

Critical Care Medicine · Orlando, FLNPI 1215923180

Payments from drug & device makers

$635,061in general payments, 2019–2025

Across 862 payments — averaging $736.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$222K
  • La Jolla Pharmaceutical Company$101K
  • Edwards Lifesciences$97K
  • Biomerieux Inc$95K
  • Acelrx Pharmaceuticals, Inc.$31K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$31K
  • plus $59K from 25 others
$4,875in research payments, 2019–2025

Across 2 payments — averaging $2437.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biomerieux Inc$5K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$635,061 in reported general payments places this provider in the 95th percentile of 618 critical care medicine providers in Florida.

See all critical care medicine providers in Florida

Medicare billing

Part B allowed, 2024
$82,953
Medicare patients
579
Services billed
738

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other critical care medicine in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →